Cangrelor and Clopidogrel interaction
Cangrelor and Clopidogrel: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Cangrelor (KENGREAL) label · effective 2025-10-21
Clopidogrel: Do not administer during KENGREAL infusion.
In CHAMPION PHOENIX bleeding events of all severities were more common with KENGREAL than with clopidogrel [see Adverse Reactions ( 6.1 )] .
Thienopyridines Clopidogrel or prasugrel administered during KENGREAL infusion will have no antiplatelet effect until the next dose is administered.
Therefore, administer clopidogrel or prasugrel after KENGREAL infusion is discontinued [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )].
From the Clopidogrel (Plavix) label · effective 2025-05-30
Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect.
Other Antiplatelet Agents Coadministration of antiplatelet agents increase the risk of bleeding due to an additive effect.
Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with other antiplatelet agents [see Warnings and Precautions (5.2) ] .
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.